FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997595732> ?p ?o ?g. }

• W1997595732 endingPage "697" @default.
• W1997595732 startingPage "689" @default.
• W1997595732 abstract "Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect. To evaluate routinely collected data on nausea and vomiting among individuals on liraglutide and their influence on tolerability and body weight. A randomized, placebo-controlled, double-blind 20-week study with an 84-week extension (sponsor unblinded at 20 weeks, open-label after 1 year) in eight European countries (Clinicaltrials.gov: NCT00422058). After commencing a 500-kcal/day deficit diet plus exercise, 564 participants (18–65 years, body mass index (BMI) 30–40 kg m−2) were randomly assigned (after a 2-week run-in period) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg), placebo or open-label orlistat (120 mg × 3 per day). After 1 year, participants on liraglutide/placebo switched to liraglutide 2.4 mg, and subsequently, to liraglutide 3.0 mg (based on 20-week and 1-year results, respectively). The intention-to-treat population comprised 561 participants (n=90–98 per arm, age 45.9±10.3 years, BMI 34.8±2.7 kg m−2 (mean±s.d.)). In year 1, more participants reported ⩾1 episode of nausea/vomiting on treatment with liraglutide 1.2–3.0 mg (17–38%) than with placebo or orlistat (both 4%, P⩽0.001). Most episodes occurred during dose escalation (weeks 1–6), with ‘mild’ or ‘moderate’ symptoms. Among participants on liraglutide 3.0 mg, 48% reported some nausea and 13% some vomiting, with considerable variation between countries, but only 4 out of 93 (4%) reported withdrawals. The mean 1-year weight loss on treatment with liraglutide 3.0 mg from randomization was 9.2 kg for participants reporting nausea/vomiting episodes, versus 6.3 kg for those with none (a treatment difference of 2.9 kg (95% confidence interval 0.5–5.3); P=0.02). Both weight losses were significantly greater than the respective weight losses for participants on placebo (P<0.001) or orlistat (P<0.05). Quality-of-life scores at 20 weeks improved similarly with or without nausea/vomiting on treatment with liraglutide 3.0 mg. Transient nausea and vomiting on treatment with liraglutide 3.0 mg was associated with greater weight loss, although symptoms appeared tolerable and did not attenuate quality-of-life improvements. Improved data collection methods on nausea are warranted." @default.
• W1997595732 created "2016-06-24" @default.
• W1997595732 creator A5012241596 @default.
• W1997595732 creator A5017679173 @default.
• W1997595732 creator A5018535962 @default.
• W1997595732 creator A5037824940 @default.
• W1997595732 creator A5048067129 @default.
• W1997595732 creator A5059778565 @default.
• W1997595732 creator A5060520170 @default.
• W1997595732 creator A5082931469 @default.
• W1997595732 date "2013-08-14" @default.
• W1997595732 modified "2023-10-10" @default.
• W1997595732 title "Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults" @default.
• W1997595732 cites W1547965481 @default.
• W1997595732 cites W1967183025 @default.
• W1997595732 cites W1969181381 @default.
• W1997595732 cites W1969856989 @default.
• W1997595732 cites W1971454182 @default.
• W1997595732 cites W1975756049 @default.
• W1997595732 cites W1984755045 @default.
• W1997595732 cites W1991249763 @default.
• W1997595732 cites W1991988767 @default.
• W1997595732 cites W1993747099 @default.
• W1997595732 cites W1994320162 @default.
• W1997595732 cites W1995394916 @default.
• W1997595732 cites W1998797154 @default.
• W1997595732 cites W2013082477 @default.
• W1997595732 cites W2039063847 @default.
• W1997595732 cites W2041488037 @default.
• W1997595732 cites W2046778213 @default.
• W1997595732 cites W2055838686 @default.
• W1997595732 cites W2066406526 @default.
• W1997595732 cites W2072056315 @default.
• W1997595732 cites W2082052031 @default.
• W1997595732 cites W2084142744 @default.
• W1997595732 cites W2097950056 @default.
• W1997595732 cites W2098459806 @default.
• W1997595732 cites W2103525547 @default.
• W1997595732 cites W2111482319 @default.
• W1997595732 cites W2111901007 @default.
• W1997595732 cites W2119754700 @default.
• W1997595732 cites W2121195629 @default.
• W1997595732 cites W2124131796 @default.
• W1997595732 cites W2125582403 @default.
• W1997595732 cites W2139470224 @default.
• W1997595732 cites W2143014102 @default.
• W1997595732 cites W2146849752 @default.
• W1997595732 cites W2148897749 @default.
• W1997595732 cites W2150137315 @default.
• W1997595732 cites W2152835319 @default.
• W1997595732 cites W2158822657 @default.
• W1997595732 cites W2163229244 @default.
• W1997595732 cites W2726799618 @default.
• W1997595732 cites W4234742542 @default.
• W1997595732 cites W4248831938 @default.
• W1997595732 doi "https://doi.org/10.1038/ijo.2013.149" @default.
• W1997595732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4010971" @default.
• W1997595732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23942319" @default.
• W1997595732 hasPublicationYear "2013" @default.
• W1997595732 type Work @default.
• W1997595732 sameAs 1997595732 @default.
• W1997595732 citedByCount "136" @default.
• W1997595732 countsByYear W19975957322014 @default.
• W1997595732 countsByYear W19975957322015 @default.
• W1997595732 countsByYear W19975957322016 @default.
• W1997595732 countsByYear W19975957322017 @default.
• W1997595732 countsByYear W19975957322018 @default.
• W1997595732 countsByYear W19975957322019 @default.
• W1997595732 countsByYear W19975957322020 @default.
• W1997595732 countsByYear W19975957322021 @default.
• W1997595732 countsByYear W19975957322022 @default.
• W1997595732 countsByYear W19975957322023 @default.
• W1997595732 crossrefType "journal-article" @default.
• W1997595732 hasAuthorship W1997595732A5012241596 @default.
• W1997595732 hasAuthorship W1997595732A5017679173 @default.
• W1997595732 hasAuthorship W1997595732A5018535962 @default.
• W1997595732 hasAuthorship W1997595732A5037824940 @default.
• W1997595732 hasAuthorship W1997595732A5048067129 @default.
• W1997595732 hasAuthorship W1997595732A5059778565 @default.
• W1997595732 hasAuthorship W1997595732A5060520170 @default.
• W1997595732 hasAuthorship W1997595732A5082931469 @default.
• W1997595732 hasBestOaLocation W19975957321 @default.
• W1997595732 hasConcept C126322002 @default.
• W1997595732 hasConcept C134018914 @default.
• W1997595732 hasConcept C142724271 @default.
• W1997595732 hasConcept C197934379 @default.
• W1997595732 hasConcept C204787440 @default.
• W1997595732 hasConcept C27081682 @default.
• W1997595732 hasConcept C2777180221 @default.
• W1997595732 hasConcept C2778375690 @default.
• W1997595732 hasConcept C2780221984 @default.
• W1997595732 hasConcept C2780580376 @default.
• W1997595732 hasConcept C2780780548 @default.
• W1997595732 hasConcept C2780852908 @default.
• W1997595732 hasConcept C2781308992 @default.
• W1997595732 hasConcept C2908647359 @default.
• W1997595732 hasConcept C511355011 @default.
• W1997595732 hasConcept C544821477 @default.

• next